SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Bill Wexler's Dog Pound
REFR 1.560-2.5%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (4278)10/9/1999 11:13:00 AM
From: DanZ  Read Replies (1) of 10293
 
Mad2 or anyone:

<By the way you confuse my comment with studies being published in NEJM with GUMM's requirement to make disclosure of material issues pertaining to their business.>

Please speculate on what will happen to the price of GUMM if the company makes the following announcements with regard to the clinical studies that are nearing completion.

1. The clinical study concludes that Zicam reduces the duration of the common cold by a similar amount to the first study ~85%.

2. The clinical study concludes that Zicam prevents the common cold.

Now, please speculate on what will happen to the price of GUMM if both studies come back inconclusive.

Thank you,

Dan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News